Seneca Biopharma Profit Margin

The latest profit margin for SNCA is -95479.92% as of December 2020. That compares with -2153.9% in the prior-year period — down 4332.9% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside Seneca Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNCA's profit margin moved from -2153.9% to -95479.92% — a 4332.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Seneca Biopharma's valuation or profitability profile.

Against Healthcare companies, SNCA currently prints -95479.92% for profit margin, while the sector average sits near 19.13%. That is roughly 499177.0% below the sector mean. Large gaps often invite a closer look at Seneca Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Seneca Biopharma converts resources into returns. At -95479.92%, SNCA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2153.9% in the prior-year period — down 4332.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SNCA's profit margin (-95479.92%), review year-over-year change from -2153.9%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.